Search results for "HIV-1"

showing 10 items of 177 documents

Antiretroviral therapy abrogates association between arginase activity and HIV disease severity

2010

AbstractArginase-induced L-arginine deprivation is emerging as a key mechanism for the downregulation of immune responses. We hypothesised that arginase activity increases with disease severity in HIV-seropositive patients. Our results show that peripheral blood mononuclear cells (PBMCs) from 23 HIV-seropositive patients with low CD4+ T cell counts (≤350 cells/μl) expressed significantly more arginase compared with 21 patients with high CD4+ T cell counts. Furthermore, we found a significant association between the two principal prognostic markers used to monitor HIV disease (CD4+ T cell count and plasma viral load) and PBMC arginase activity in antiretroviral therapy naïve patients but not…

MaleAnti-HIV AgentsT cellT cellsCD4 cell countL-arginineHIV InfectionsArgininePeripheral blood mononuclear cellSeverity of Illness Index03 medical and health sciences0302 clinical medicineImmune systemImmunopathologymedicineHumansImmune response030304 developmental biology0303 health sciencesbiologyArginasebusiness.industryPublic Health Environmental and Occupational HealthHIVGeneral MedicineViral Loadbiology.organism_classification3. Good healthCD4 Lymphocyte CountArginaseInfectious Diseasesmedicine.anatomical_structureSociety Meeting PaperLentivirusImmunologyHIV-1Leukocytes MononuclearParasitologyFemaleViral diseasebusinessViral load030217 neurology & neurosurgeryTransactions of the Royal Society of Tropical Medicine and Hygiene
researchProduct

Differential in vitro Anti-HIV Activity of Natural Lignans

1990

Abstract Two naturally occurring lignanolides, isolated from the tropical climbing shrub Ipomoea cairica, (-)-arctigen in and (-)-trachelogen in , were found to inhibit strongly replication of human immunodeficiency virus type 1 (HIV-1; strain HTLV-III B) in vitro. At a concentration of 0.5 (μм , (-)-arctigenin and (-)-trachelogenin inhibited the expression of HIV-1 proteins p 17 and p24 by 80 -90 % and 60 -70 % , respectively. The reverse transcriptase activity in the cul­ture fluids was reduced by 80 -90 % when the cells (HTLV-III B/H 9) were cultivated in the presence of 0.5 μм (-)-arctigen in or 1 μм (-)-trachelogenin . At the same concentrations, the formation of syncytia in the HTLV-I…

Antiviral AgentsLigninLignansGeneral Biochemistry Genetics and Molecular BiologyCell LineMiceStructure-Activity RelationshipViral Proteinschemistry.chemical_compoundAnimalsHumansLeukemia L5178Lignanchemistry.chemical_classificationbiologyTopoisomeraseHIVvirus diseasesDNA topoisomerase II activityMolecular biologyReverse transcriptaseIn vitroDNA Topoisomerases Type IIEnzymechemistryViral replicationCell cultureHIV-1biology.proteinCell DivisionPlasmidsZeitschrift für Naturforschung C
researchProduct

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

2005

Summary Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

AdultCD4-Positive T-LymphocytesMaleImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsMatrix metalloproteinasemedicine.disease_causeMMP-7; Fas ligand; CD4T cells; HIV infectionFas ligandPlasma viral loadGeneticsHumansMedicineMolecular BiologyGenetics (clinical)Polymorphism Geneticbusiness.industryMetalloendopeptidasesGeneral MedicineMiddle AgedViral LoadAntiretroviral therapySoluble fas ligandCD4 Lymphocyte CountAnti-Retroviral AgentsApoptosisMatrix Metalloproteinase 7ImmunologyHIV-1business
researchProduct

Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1

2012

Abstract MicroRNAs (miRNAs) inhibit HIV-1 expression by either modulating host innate immunity or by directly interfering with viral mRNAs. We evaluated the expression of 377 miRNAs in CD4+ T cells from HIV-1 élite long-term nonprogressors (éLTNPs), naive patients, and multiply exposed uninfected (MEU) patients, and we observed that the éLTNP patients clustered with naive patients, whereas all MEU subjects grouped together. The discriminatory power of miRNAs showed that 21 miRNAs significantly differentiated éLTNP from MEU patients and 23 miRNAs distinguished naive from MEU patients, whereas only 1 miRNA (miR-155) discriminated éLTNP from naive patients. We proposed that miRNA expression ma…

AdultCD4-Positive T-LymphocytesMaleTime FactorsImmunologyHIV InfectionsHIV Envelope Protein gp120BiologyBiochemistryImmune systemmultiply exposed uninfectedmicroRNAHumansDroshamiRNAInnate immune systemélite long-term nonprogressorsGene Expression ProfilingCell BiologyHematologyT lymphocyteMiddle AgedViral LoadMicroarray AnalysisHIV-1; miRNA; CD4+ T cells; élite long-term nonprogressors; multiply exposed uninfected.CD4+ T cellsIn vitroMicroRNAsGene Expression RegulationCase-Control StudiesImmunologyHIV-1biology.proteinFemaleEx vivoDicerBlood
researchProduct

Weighted Least-Squares Likelihood Ratio Test for Branch Testing in Phylogenies Reconstructed from Distance Measures

2005

A variety of analytical methods is available for branch testing in distance-based phylogenies. However, these methods are rarely used, possibly because the estimation of some of their statistics, especially the covariances, is not always feasible. We show that these difficulties can be overcome if some simplifying assumptions are made, namely distance independence. The weighted least-squares likelihood ratio test (WLS-LRT) we propose is easy to perform, using only the distances and some of their associated variances. If no variances are known, the use of the Felsenstein F-test, also based on weighted least squares, is discussed. Using simulated data and a data set of 43 mammalian mitochondr…

MammalsLikelihood FunctionsModels GeneticReproducibility of ResultsGeneralized least squaresClassificationDNA MitochondrialDistance measuresEvolution MolecularData setData Interpretation StatisticalLikelihood-ratio testStatisticsHIV-1GeneticsAnimalsCluster AnalysisPoint (geometry)PhylogenyEcology Evolution Behavior and SystematicsIndependence (probability theory)Reliability (statistics)Selection (genetic algorithm)MathematicsSystematic Biology
researchProduct

Characterization of new recombinant forms of HIV-1 from the Comunitat Valenciana (Spain) by phylogenetic incongruence

2019

Recombination is one of the main processes shaping the evolution of HIV-1, with relevant consequences for its epidemiology. In fact, Circulating and Unique Recombinant Forms (CRFs and URFs) cause 23% of current infections. The routine analyses of antiretroviral resistance yield partial pol gene sequences that can be exploited for molecular epidemiology surveillance but also to study viral diversity and to detect potential recombinant samples. Among the pol sequences derived from a large sample dataset from the Comunitat Valenciana (Spain), we identified nine putative recombinant samples. We aimed at fully characterizing these samples and performing a detailed analysis of the corresponding r…

Microbiology (medical)Pol genesHuman immunodeficiency virus (HIV)lcsh:QR1-502Computational biologyBiologymedicine.disease_causephylogenyMicrobiologylcsh:Microbiologylaw.invention03 medical and health scienceslawPhylogeneticsCRFsmedicineCRFSOriginal Research030304 developmental biology0303 health sciencesMolecular epidemiologyPhylogenetic tree030306 microbiologynearly-full genomeURFsrecombinationRecombinant DNAHIV-1Recombination
researchProduct

Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized…

2016

International audience; IMPORTANCE:Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce.OBJECTIVE:To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen.DESIGN, SETTING, AND PARTICIPANTS:The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than…

0301 basic medicineMaleHIV Infectionsmedicine.disease_causelaw.inventionMESH: HIV-10302 clinical medicineRandomized controlled triallawSingle-Blind Method030212 general & internal medicineMESH: Hepatitis B AntibodiesMESH: Treatment Outcomeeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: Middle AgedVaccinationMESH: Follow-Up StudiesMESH: HIV InfectionsHepatitis BMiddle Aged16. Peace & justiceHepatitis BMESH: Injections Intramuscular3. Good healthVaccinationTreatment OutcomeFemaleFranceIntramuscular injectionAdultmedicine.medical_specialtyHepatitis B vaccineInjections Intradermal030106 microbiologyPopulationInjections Intramuscular03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B virusMESH: Injections IntradermalMESH: Hepatitis B VaccinesMESH: HumansMESH: Hepatitis Bbusiness.industryMESH: AdultMESH: Vaccinationmedicine.diseaseMESH: Single-Blind MethodMESH: MaleSurgeryMESH: FranceRegimenHIV-1MESH: BiomarkersbusinessMESH: FemaleBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Rev protein suppression of complex formation between nuclear proteins and rev-responsive element-containing RNA of human immunodeficiency virus-1

1995

The Rev protein from human immunodeficiency virus type 1 (HIV-1) is known to bind Rev responsive element (RRE) sequence of HIV-1 mRNA. This interaction is thought to enhance expression of viral structural proteins but the mechanism for this effect is uncertain. The aim of this study was to investigate (i) whether other cellular proteins also bind to the RRE sequence and (ii) whether binding of cellular proteins to RRE RNA is influenced by Rev protein. Our results revealed that a variety of RNA-protein complexes are formed when in vitro transcribed RRE-containing RNA is incubated with proteins present in HeLa nuclear extracts. The molecular masses of the most prominent bands in RNase protect…

RNase PvirusesBiologyGenes envBiochemistrylaw.inventionchemistry.chemical_compoundBiopolymerslawHumansRNA MessengerNuclear proteinRibonucleoproteinMessenger RNANuclear ProteinsRNArev Gene Products Human Immunodeficiency VirusCell BiologyMolecular biologyCell biologyGene Products revRibonucleoproteinschemistryCytoplasmHIV-1Recombinant DNARNA ViralPMSFHeLa CellsThe International Journal of Biochemistry & Cell Biology
researchProduct

Structure-Based Design of an RNA-Bindingp-Terphenylene Scaffold that Inhibits HIV-1 Rev Protein Function

2013

Hiv 1 revScaffoldAnti-HIV AgentsStereochemistryHuman immunodeficiency virus (HIV)Virus Replicationmedicine.disease_causeCatalysisStructure-Activity RelationshipTerphenyl CompoundsmedicineHumansProtein functionBinding SitesDose-Response Relationship DrugMolecular StructureChemistryRNArev Gene Products Human Immunodeficiency VirusGeneral MedicineGeneral ChemistrySmall moleculeDrug DesignHIV-1RNAStructure basedAngewandte Chemie International Edition
researchProduct

Avarol restores the altered prostaglandin and leukotriene metabolism in monocytes infected with human immunodeficiency virus type 1

1991

Abstract Infection of monocytes with human immunodeficiency virus type 1 (HIV-1) (strain Ada-M) caused increased levels of leukotriene B 4 (LTB 4 ) and prostaglandin E 2 (PGE 2 ) in vitro. These two products result from the activities of the two enzymes cyclooxygenase and 5-lipoxygenase. The addition of the sesquiterpenoid hydroquinone Avarol, an HIV inhibitor, strongly reduced the levels of LTB 4 and PGE 2 via inhibition of both cyclooxygenase and lipoxygenase in monocytes. The 50% inhibition concentrations (IC 50 ) for the enzymes were determined to be 2.26 μM (cyclooxygenase) and 1.97 μM (lipoxygenase). A 50% reduction of the extent of PGE 2 and LTB 4 production in HIV-infected monocytes…

Cancer ResearchLeukotriene B4medicine.medical_treatmentProstaglandinBiologyAntiviral AgentsLeukotriene B4DinoprostoneMonocytesLipoxygenasechemistry.chemical_compoundVirologymedicineCyclooxygenase InhibitorsLipoxygenase InhibitorsProstaglandin E2Arachidonate 5-LipoxygenaseMonocyteMolecular biologyInfectious Diseasesmedicine.anatomical_structurechemistryBiochemistryProstaglandin-Endoperoxide SynthasesArachidonate 5-lipoxygenaseHIV-1biology.proteinCyclooxygenaseSesquiterpenesProstaglandin Emedicine.drugVirus Research
researchProduct